Cosmos Health Q3 revenue rises to record high on contract manufacturing

Cosmos Health

07/10/2026 14:47

Overview
US healthcare group's preliminary Q3 revenue rose 2% yr/yr to a company record
Company reaffirmed outlook for full-year 2026 revenue to surpass $90 mln
Growth driven by contract manufacturing, pharmaceutical distribution, and proprietary brands

Outlook
Cosmos Health reaffirms full-year 2026 revenue will surpass $90 mln
Company expects Q4 2026 to be its strongest quarter, driven by contract manufacturing and US sales

Result Drivers
CONTRACT MANUFACTURING - Co said record production pipeline at Cana Laboratories drove revenue growth
PHARMACEUTICAL DISTRIBUTION - Record distribution volumes at CosmoFarm contributed to revenue increase
PROPRIETARY BRANDS - Co said proprietary brands grew in established markets and expanded into new territories, with building sales momentum in US

Company press release: ID:nACSv1lZMa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$17.40 mln
$20.89 mln (1 Analyst)

Analyst Coverage
Wall Street's median 12-month price target for Cosmos Health Inc is $4.50, about 1,308.5% above its October 6 closing price of $0.32
The stock recently traded at 0 times the next 12-month earnings vs. a P/E of 5 three months ago

Reuters Recommended Reads
Oct 6 - Neogen Q1 results beat estimates on Food Safety segment growth, raises FY27 guidance
Oct 6 - Apogee Enterprises Q2 sales ease past estimates; annual outlook lifted
     

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)